Literature DB >> 19530255

Absence of IDH2 codon 172 mutation in common human cancers.

Sang Wook Park, Nak Gyun Chung, Ji Youn Han, Hyeon Seok Eom, Ji Youl Lee, Nam Jin Yoo, Sug Hyung Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19530255     DOI： 10.1002/ijc.24647

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.316


× No keyword cloud information.
  6 in total

1.  Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.

Authors:  Craig Horbinski; Julia Kofler; Gabrielle Yeaney; Sandra Camelo-Piragua; Sriram Venneti; David N Louis; Arie Perry; Geoffrey Murdoch; Marina Nikiforova
Journal:  Brain Pathol       Date:  2011-03-14       Impact factor: 6.508

2.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

3.  Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.

Authors:  Farhad Ravandi; Keyur Patel; Rajyalakshmi Luthra; Stefan Faderl; Marina Konopleva; Tapan Kadia; Mark Brandt; Sherry Pierce; Steven Kornblau; Michael Andreeff; Xuemei Wang; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.921

Review 4.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.

Authors:  Zachary J Reitman; Hai Yan
Journal:  J Natl Cancer Inst       Date:  2010-05-31       Impact factor: 11.816

Review 5.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

6.  An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.

Authors:  Gang Xiao; Xuan Gao; Lifeng Li; Chao Liu; Zhiyuan Liu; Haiqin Peng; Xuefeng Xia; Xin Yi; Rongrong Zhou
Journal:  J Oncol       Date:  2021-12-18       Impact factor: 4.375
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.